Home/Pipeline/TAC-001

TAC-001

Solid Tumors

Phase 1/2Active

Key Facts

Indication

Solid Tumors

Phase

Phase 1/2

Status

Active

Company

Tallac Therapeutics

About Tallac Therapeutics

Tallac Therapeutics is an innovative, clinical-stage biotech pioneering a novel class of immunostimulatory antibody-drug conjugates (ADCs). The company's TRAAC platform conjugates oligonucleotide payloads, like TLR9 agonists, to antibodies, aiming to precisely deliver immune-activating signals to the tumor while minimizing systemic toxicity. With two programs in the clinic, including lead candidate TAC-001 which has received FDA Fast Track designation, Tallac is advancing a pipeline designed to harness both innate and adaptive immunity against cancer. The company is privately held, founded in 2019, and based in San Mateo, California.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed
Undisclosed Whole Cell Vaccine Program(s)	Neuvogen	Pre-clinical	Active
SY-5609	Syros Pharmaceuticals	Phase 1/2	Discontinued
Not Specified (TCR Therapy)	T-Cure Bioscience	Phase 1	Active
B7-H3 Program	Ocean Biomedical	Discovery	Active